Abstract
The utility of primary human hepatocytes in the evaluation of drug-drug interactions is being investigated in our laboratories. Our initial approach was to investigate whether drug-drug interactions observed in humans in vivo could be reproduced in vitro using human hepatocytes. Two model drugs were studied: terfenadine and rifampin, representing compounds subjected to drug-drug interactions via inhibitory and induction mechanisms, respectively. Terfenadine was found to be metabolized by human hepatocytes to C-oxidation and N-dealkylation products as observed in humans in vivo. Metabolism by human hepatocytes was found to be inhibited by drugs which are known to be inhibitory in vivo, Ki values for the various inhibitors were derived from the in vitro metabolism data, resulting in the following ranking of inhibitory potency: For the inhibition of C-oxidation, ketoconazole > itraconazole > cyclosporin ~ troleandomycin > erythromycin > naringenin. For the inhibition of N-dealkylation, itraconazole ≥ ketoconazole > cyclosporin ≥ naringenin ≥ erythromycin ≥ troleandomycin. Rifampin induction of CYP3A, a known effect of rifampin in vivo, was also reproduced in primary human hepatocytes. Induction of CYP3A4, measured as testosterone 6β-hydroxylation, was found to be dose-dependent, treatment duration-dependent, and reversible. The induction effect of rifampin was observed in hepatocytes isolated from all 7 human donors studied, with ages ranging from 1.7 to 78 years. To demonstrate that the rifampin-induction of testosterone 6β-hydroxylation could be generalized to other CYP3A4 substrates, we evaluated the metabolism of another known substrate of CYP3A4, lidocaine. Dose-dependent induction of lidocaine metabolism by rifampin is observed. Our results suggest that primary human hepatocytes may be a useful experimental system for preclinical evaluation of drug-drug interaction potential during drug development, and as a tool to evaluate the mechanism of clinically observed drug-drug interactions.
Similar content being viewed by others
References
Badcock NR, Bartholomeusz FD, Frewin DB, Sansom LN, Reid JG. The pharmacokinetics of ketoconazole after chronic administration in adults. Eur J Clin Pharmacol. 1987;33:531–4.
Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIA. Clin Pharmacol Ther. 1989;46:521–7.
Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, result-ing in prolongation of repolarization on the electrocardio-gram. Clin Pharmacol. 1996;59:383–8.
Burke MD, Mayer RT. Different effects of phenobarbitone and 3-methylcholanthrene induction of the hepatic microsomal metabolism and cytochrome P450 binding of phenoxazone and a homologous series of its n-alkyl ethers. Chem Biol Interact. 1993;45:243–58.
Daneshmend T, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet. 1988;14:13–34.
D'Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm. 1986;20:353–62.
Dellerich M, Raude E, Burdelski M et al. Monoethylglycine-xylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem. 1987;25:845–53.
Donato MT, Castell NV, Gomez-Lechon MJ. Effect of model inducers on cytochrome P450 activities of human hepato-cytes in primary culture. Drug Metab Dispos. 1995;23:256–8.
Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharma-cokinet. 1993;24:472–95.
Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45:953–1040.
FDA. Warnings issued on nonsedating antihistamines terfena-dine and astemizole. J Am Med Assoc. 1992;268:705.
Gartiez DA, Hook RH, Walker BJ, Okerholm RA. Pharmaco-kinetics and biotransformation studies of terfenadine in man. Arzneim Forsch Drug Res. 1982;32:1185–90.
Ged C, Roullion JM, Pichard L et al. The increase in urinary excretion of 6b-hydroxycortisol as a marker for human hepatic cytochrome P450 IIIA induction. Br J Clin Pharma-col. 1989;38:373–87.
Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev. 1989;40:243–88.
Grange JM, Winstanley PA, Davies PD. Clinically significant drug interactions with antituberculosis agents. Drug Safety. 1994;11:242–51.
Grant SM, Clissold SP. Itraconazole: A review of its pharma-codynamic and pharmacokinetic properties, and therapeu-tic use in superficial and systemic mycoses. Drugs. 1989;37: 310–44.
Guengerich FP. Metabolism of 17α-ethynylestradiol in humans. Life Sci. 1990;47:1981–8.
Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: phar-macokinetics and electrocardiographic consequences. J Am Med Assoc. 1993a;269:1513–18
Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacody-namics. J Clin Pharmacol. 1993b;33:1201–6.
Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolar-ization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol. 1996;36:345–51.
Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Phar-macol. 1992;44:275–83.
Imaoka S, Enomoto K, Yutaka O et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic micro-somes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther. 1990;255:1385–91.
Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos. 1994;22:849–57.
Jurima-Romet M, Huang HS, Beck DJ, Li AP. Evaluation of drug interactions in intact hepatocytes: inhibitors of terfe-nadine metabolism. Toxicol In Vitro. 1996;10:655–63.
Li AP. Primary human hepatocytes as an experimental system in toxicology and drug metabolism. Comments Toxicol. [in press].
Li AP, Roque MA, Beck DJ, Kaminski DL. Isolation and culturing of hepatocytes from human liver. J Tissue Culture Methods. 1992;14:139–46.
Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P4503A4. Toxicology. 1995a;104:1–8. Li AP, Rasmussen A, Xu L, Kaminski DL. Rifampicin induc-tion of lidocaine metabolism in cultured human hepato-cytes. J Pharmacol Exp Ther. 1995b;274:673-7.
Loretz LJ, Li AP, Flye MW, Wilson AGE. Optimization of cryopreservation procedures for rat and human hepato-cytes. Xenobiotica. 1989;19:489–98. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in associa-tion with terfenadine use. J Am Med Assoc. dy1990;264:2788-90.
Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics: effects of age and various pathophysiological states. Clin Pharmacokinet. 1989;16:193–214.
Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol. 1992;41: 1047–55.
Pohjala-Sintonen S, Viitsalo M, Toivonen L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interac-tion. Br Med J. 1993;306:186.
Reimers D, Nocke-Finck L, Breuer H. Rifampicin and the "pill" do not go well together. J Am Med Assoc. 1974;227: 608.
Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkin-son A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P450. Arch Biochem Biophys. 1987;255:27–41.
Strolin Benedetti M, Dostert P. Induction and autoinduction of rifamycin derivatives: a review of animal and human stu-dies. Environ Health Perspect. 1994;102:101–5.
Woosley RL, ChenY, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc. 1993; 269:1532–6.
Yun CH, Okerholm A, Guengerich FP. Oxidation of the antihistamine drug terfenadine in human liver microsomes. Role of cytochrome P4503A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos. 1993;21:403–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, A., Jurima-Romet, M. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol 13, 365–374 (1997). https://doi.org/10.1023/A:1007451911843
Issue Date:
DOI: https://doi.org/10.1023/A:1007451911843